Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...
|
The Phase 3 PURPOSE 1 trial for lenacapavir in HIV
prevention showed 100% efficacy, generating excitement and potential for a
broader population reach ... |